Yale School of Medicine, Department of Psychiatry, New Haven, CT, 06511, United States; APT Foundation Pain Treatment Services, New Haven, CT, 06519, United States.
Yale School of Medicine, Department of Psychiatry, New Haven, CT, 06511, United States; APT Foundation Pain Treatment Services, New Haven, CT, 06519, United States.
Drug Alcohol Depend. 2019 Jan 1;194:460-467. doi: 10.1016/j.drugalcdep.2018.10.015. Epub 2018 Nov 13.
The primary study aim was to evaluate the feasibility and acceptability of cognitive-behavioral therapy (CBT) for opioid use disorder and chronic pain. The secondary aim was to examine its preliminary efficacy.
In a 12-week pilot randomized clinical trial, 40 methadone-maintained patients were assigned to receive weekly manualized CBT (n = 21) or Methadone Drug Counseling (MDC) to approximate usual drug counseling (n = 19).
Twenty of 21 patients assigned to CBT and 18 of 19 assigned to MDC completed the pilot study. Mean (SD) sessions attended were 8.4 (2.9) for CBT (out of 12 possible) and 3.8 (1.1) for MDC (out of 4 possible); mean (SD) patient satisfaction ratings (scored on 1-7 Likert-type scales) were 6.6 (0.5) for CBT and 6.0 (0.4) for MDC (p < .001). The proportion of patients abstinent during the baseline and each successive 4-week interval was higher for patients assigned to CBT than for those assigned to MDC [Wald χ (1) = 5.47, p = .02]; time effects (p = .69) and interaction effects between treatment condition and time (p = .10) were not significant. Rates of clinically significant change from baseline to end of treatment on pain interference (42.9% vs. 42.1%, [χ (1, N = 40) = 0.002, p = 0.96]) did not differ significantly for patients assigned to CBT or MDC.
We found support for the feasibility, acceptability, and preliminary efficacy of cognitive-behavioral therapy relative to standard drug counseling in promoting abstinence from nonmedical opioid use among patients with opioid use disorder and chronic pain. Overall, patients exhibited improved pain outcomes, but these improvements did not differ significantly by treatment condition.
本研究的主要目的是评估认知行为疗法(CBT)治疗阿片类药物使用障碍和慢性疼痛的可行性和可接受性。次要目的是检验其初步疗效。
在一项为期 12 周的试点随机临床试验中,将 40 名美沙酮维持治疗患者随机分配至每周接受手册化 CBT(n=21)或美沙酮药物咨询(MDC),以近似于常规药物咨询(n=19)。
21 名分配至 CBT 的患者和 19 名分配至 MDC 的患者中各有 20 名完成了该试点研究。接受 CBT 的患者(12 次可能就诊中)的平均就诊次数为 8.4(2.9),接受 MDC 的患者(4 次可能就诊中)的平均就诊次数为 3.8(1.1);患者满意度评分(1-7 级 Likert 量表)的平均(SD)评分分别为 6.6(0.5)和 6.0(0.4)(p<0.001)。与分配至 MDC 的患者相比,分配至 CBT 的患者在基线和每个后续 4 周间隔的无药物使用比例更高[Wald χ(1)=5.47,p=0.02];时间效应(p=0.69)和治疗条件与时间的交互效应(p=0.10)不显著。与基线相比,在治疗结束时,接受 CBT 和 MDC 的患者的疼痛干扰的临床显著变化率(分别为 42.9%和 42.1%,[χ(1, N=40)=0.002,p=0.96])无显著差异。
我们发现,与标准药物咨询相比,认知行为疗法在促进阿片类药物使用障碍和慢性疼痛患者戒除非医疗用阿片类药物方面具有可行性、可接受性和初步疗效。总体而言,患者的疼痛结局有所改善,但治疗条件无显著差异。